Drug intelligence / Profile preview

ammonium lactate

Development stage: Approved
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Topical

Overview

Ammonium lactate is a synthetic alpha-hydroxy acid (AHA) formulated as a topical humectant and keratolytic agent. It is primarily used to treat dry, scaly skin conditions such as xerosis and ichthyosis vulgaris, and has been investigated as a monotherapy or maintenance treatment for chronic plaque psoriasis. The drug works by increasing skin hydration through its humectant properties and promoting the shedding of dead skin cells (desquamation) by reducing corneocyte adhesion in the stratum corneum. It is commonly available in 12% concentrations as a lotion or cream.

Brand names: AmLactinLac-HydrinGeri-Hydrolac
Other names: Lactic acid ammonium saltAmmonium 2-hydroxypropanoateAmmonium2-hydroxypropanoateAmmonium-2-hydroxypropanoate

Beyond the preview

Go deeper on ammonium lactate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ammonium lactate.

Explore the full profile